{"id":14097,"date":"2017-10-23T08:27:26","date_gmt":"2017-10-23T08:27:26","guid":{"rendered":"https:\/\/celonpharma.com\/?p=14097"},"modified":"2017-10-23T08:27:26","modified_gmt":"2017-10-23T08:27:26","slug":"celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/","title":{"rendered":"Celon Pharma S.A. receives a positive recommendation of the National Centre for Research and Development o co-funding of the development of the drug candidate for treatment of type 2 diabetes"},"content":{"rendered":"<blockquote>\n<p style=\"text-align: justify;\"><strong>Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.:<\/strong> <em>We are very pleased about it. Our application was received a very good grade in the expert assessment and was placed high on the ranking.\u00a0This project in the area of metabolic diseases is currently very important to us. First we are facing toxicological tests, and after they have been completed, we will apply for the first administration of the drug in humans. We want to commence clinical development in 2018.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Jerzy Pieczykolan, PhD, Head of the Preclinical Research Department in Celon Pharma S.A:<\/strong> \u00a0<em>esults of the TTG in vivo test carried out on animals confirm our compound\u2019s high activity and high effectiveness. GPR40 agonists can potentially constitute a good and safer alternative for the group of patients resistant to treatment with e.g. metformin. Additionally, these compounds do not increase the risk of hypoglycaemia<\/em><\/p>\n<\/blockquote>\n<p style=\"text-align: justify;\"The recommended amount of the project co-funding is PLN 24.8 million. \u00a0In accordance with the agreement concluded with Plexus Ventures, the project has been covered by the global commercialisation strategy of the Company\u2019s innovative portfolio.<\/p>\n<p style=\"text-align: justify;\">The Company\u2019s application was submitted under the Smart Growth Operational Programme 2014-2020 Programme, measure 1.1\/submeasure 1.1.1. regarding the following project: \u201cPreclinical and clinical development of an innovative antagonist of GPR40 receptor in type 2 diabetes treatment\u201d.<\/p>\n<p style=\"text-align: justify;\">Its total cost is estimated at PLN 39.4 and the recommended value of co-funding in PLN 24.8. The project will be implemented by 2022.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.: We are very pleased about it. Our application was received a very good grade in the expert assessment and was placed high on the ranking.\u00a0This project in the area of metabolic diseases is currently very important to us. First we are facing toxicological tests,<a class=\"excerpt-read-more float-right\" href=\"https:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/\" title=\"ReadCelon Pharma S.A. receives a positive recommendation of the National Centre for Research and Development o co-funding of the development of the drug candidate for treatment of type 2 diabetes\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[],"class_list":["post-14097","post","type-post","status-publish","format-standard","hentry","category-general-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Celon Pharma S.A. receives a positive recommendation of the National Centre for Research and Development o co-funding of the development of the drug candidate for treatment of type 2 diabetes - CelonGROUP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celon Pharma S.A. receives a positive recommendation of the National Centre for Research and Development o co-funding of the development of the drug candidate for treatment of type 2 diabetes - CelonGROUP\" \/>\n<meta property=\"og:description\" content=\"Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.: We are very pleased about it. Our application was received a very good grade in the expert assessment and was placed high on the ranking.\u00a0This project in the area of metabolic diseases is currently very important to us. First we are facing toxicological tests,Read more &raquo;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"CelonGROUP\" \/>\n<meta property=\"article:published_time\" content=\"2017-10-23T08:27:26+00:00\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/\",\"url\":\"http:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/\",\"name\":\"Celon Pharma S.A. receives a positive recommendation of the National Centre for Research and Development o co-funding of the development of the drug candidate for treatment of type 2 diabetes - CelonGROUP\",\"isPartOf\":{\"@id\":\"https:\/\/celon.group\/en\/#website\"},\"datePublished\":\"2017-10-23T08:27:26+00:00\",\"author\":{\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\"},\"breadcrumb\":{\"@id\":\"http:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/celon.group\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celon Pharma S.A. receives a positive recommendation of the National Centre for Research and Development o co-funding of the development of the drug candidate for treatment of type 2 diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/celon.group\/en\/#website\",\"url\":\"https:\/\/celon.group\/en\/\",\"name\":\"CelonGROUP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/celon.group\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\",\"name\":\"Ma\u0142gorzata Siewierska\",\"url\":\"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celon Pharma S.A. receives a positive recommendation of the National Centre for Research and Development o co-funding of the development of the drug candidate for treatment of type 2 diabetes - CelonGROUP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/","og_locale":"en_US","og_type":"article","og_title":"Celon Pharma S.A. receives a positive recommendation of the National Centre for Research and Development o co-funding of the development of the drug candidate for treatment of type 2 diabetes - CelonGROUP","og_description":"Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.: We are very pleased about it. Our application was received a very good grade in the expert assessment and was placed high on the ranking.\u00a0This project in the area of metabolic diseases is currently very important to us. First we are facing toxicological tests,Read more &raquo;","og_url":"http:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/","og_site_name":"CelonGROUP","article_published_time":"2017-10-23T08:27:26+00:00","author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/","url":"http:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/","name":"Celon Pharma S.A. receives a positive recommendation of the National Centre for Research and Development o co-funding of the development of the drug candidate for treatment of type 2 diabetes - CelonGROUP","isPartOf":{"@id":"https:\/\/celon.group\/en\/#website"},"datePublished":"2017-10-23T08:27:26+00:00","author":{"@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf"},"breadcrumb":{"@id":"http:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/celon.group\/en\/2017\/10\/23\/celon-pharma-s-a-receives-a-positive-recommendation-of-the-national-centre-for-research-and-development-o-co-funding-of-the-development-of-the-drug-candidate-for-treatment-of-type-2-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celon.group\/en\/"},{"@type":"ListItem","position":2,"name":"Celon Pharma S.A. receives a positive recommendation of the National Centre for Research and Development o co-funding of the development of the drug candidate for treatment of type 2 diabetes"}]},{"@type":"WebSite","@id":"https:\/\/celon.group\/en\/#website","url":"https:\/\/celon.group\/en\/","name":"CelonGROUP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celon.group\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf","name":"Ma\u0142gorzata Siewierska","url":"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/"}]}},"_links":{"self":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/14097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/comments?post=14097"}],"version-history":[{"count":0,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/14097\/revisions"}],"wp:attachment":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/media?parent=14097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/categories?post=14097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/tags?post=14097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}